Dexa Group Through PT Ferron Par Pharmaceuticals Won Primaniyarta Award 2019

PT Ferron Par Pharmaceuticals won Primaniyarta 2019 for the Global Brand Developer Exporter category. The award was given by the Vice President of the Republic of Indonesia Mr. Jusuf Kalla to Chairman of Dexa Group, Mr. Ferry Soetikno, at the opening of Trade Expo Indonesia, at ICE BSD Banten, on Wednesday, October 16, 2019.
Primaniyarta Award is the greatest reward given by the Government of the Republic of Indonesia to the most successful Indonesian exporters and to them who can be the role model for the other Indonesian exporters. This Primaniyarta award, is an annual event organized by the government through the Directorate General of Export Development Ministry of Trade.

"We want to communicate to our trading partners and the world of the potential, continuity of our trade and industry capabilities. Also for the progress that made by Indonesia in various fields to increase trade and economy at the same time," said Mr. Jusuf Kalla in his speech.Ferron became the top finalists on Global Brand Developer Exporter category in Primaniyarta 2019, , followed by four other finalists.

Become The World Class Pharmacuetical
The successful of Ferron on Primaniyarta 2019 because of the perseverance and persistence to penetrate the market with strict pharmaceutical industry regulation such as the UK, the Netherlands, and Poland.

"Ferron being the first Indonesian pharmaceutical company that succeed developing products with diabetes Metformin Sustained Release technology that penetrate export markets of the UK, the Netherlands and Poland," said Dexa Group Chairman Mr. Ferry Soetikno on event ICE Trade Expo Indonesia in BSD Tangerang, Banten, October 16, 2019.

The most key importance is about price competitiveness, production facilities with the systems and culture of good quality, product development competencies that meet by the rules and regulations also standards applicable in the European region. Also, Ferron has been committed for the sources of raw materials that meet requirements quality, requirements of supporting documents, registration of intellectual property rights, and consistently to build commitment to product development competencies in accordance with the habitat regulatory that support by infrastructure of Research and Development, at last but not least, a competent human resources on team.

On March 2008, PT Ferron Par Pharmaceuticals achieved the excellent results from the audit Medicine and Healthcare Products Regulatory Agency (MHRA) as the competent institution that dealing with the problem of drugs in the UK. Finally on July 21, 2008 Ferron successfully conducted prime export to the UK.

From the high demand from diabetics Metformin product in the UK, Ferron become a number two pharmaceutical companies in the UK with a market share of around 25% for products Sustain Release Metformin.

A drug production that contain Metformin Sustained Release Ferron as well known by the Glucient SR brand applied in the National Health Care System in the United Kingdom. This product used to treat patients with diabetes in the UK, with prevalence of 6% of the total population.

At the end of 2018 Ferron with Metformin Sustained Release product also succeed to penetrate the Dutch market. And on July 2, 2019, the Metformin Sustained Release product also achieved to penetrate the Polish market.

Date Release: 
Friday, October 18, 2019 - 14:30